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A B ST R AC T  
 
Aim: To evaluate the effect of local anesthesia types on erectile function during transrectal 
ultrasound guided biopsy (TRUS-Bx). 
Methods: Between February 2014 and February 2015, 50 men who underwent TRUS-Bx at our 
institution were included in this prospective study. The 50 patients were randomized and divided 
into two groups according to the type of anesthesia used. All patients were asked to indicate the level 
of pain experienced on a visual analogue scale (VAS) 10 min after the TRUS biopsy. All patients 
had to fill in the IIEF standardized questionnaire. Groups were evaluated in terms of pre-biopsy IEFF 
score (IIEF-1), post-biopsy 1st month IIEF score (IIEF-2) and post-biopsy 2nd month IIEF score 
(IIEF -3). Patient characteristics, mean VAS score and IIEF score were compared between the two 
groups. 
Results: The mean age, IIEF-1, tPSA level, prostate volume and VAS score were 60.86±0.95 years, 
18.68,6.81±0.54 ng/ml, 51.10±3.82 cc and 3.5±0.26 in all patients, respectively. The difference in 
VAS scores between the groups was statistically significant. In Group 1 the IIEF-1, IIEF-2, and IIEF-
3 were different from each other statistically. There was no statistically significant difference 
between IIEF-1 and IIEF-3 scores in group 2. So it was observed that the initial IIEF scores were 
reached at the end of the second month in group 2 administered 12.5 g 2% lidocaine HCl gel. 
Conclusion: Our study indicates that although local periprostatic anesthesia by injecting 6 ml of 2% 
lidocaine provides more effective anesthesia for pain relief, intrarectal 12.5g 2% lidocaine HCl gel 
maintains less impact on erectile dysfunction for TRUS-Bx.  
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Introduction 
Prostate cancer is the most common 
malignancy in males and is the second most 
common cause of death due to malignancy [1]. 
Screening, detection and diagnosis of prostate 
cancer are currently based on serum prostate-
specific antigen (PSA) level, digital rectal 
examination (DRE) and transrectal ultrasound 
guided biopsies (TRUS-Bx). Transrectal 
prostate needle biopsy (TPNB) has been the 
standard urological procedure to detect 
prostate cancer since it was introduced by 
Hodge et al. [2]. Although it is well tolerated 
by many patients, the procedure can cause 
significant pain and discomfort [3]. Both 
clinical and laboratory experience have shown 
that TRUS-Bx is associated with considerable 
pain and anxiety and may interfere with sexual 
function and potency [4,5]. 
In the international literature, studies have 
investigated the effect of TRUS-Bx on erectile 
dysfunction (ED). Most have demonstrated 
that these post-biopsy effects occur over a 
short period of time and are transient [5-9]. 
Several theories and hypotheses regarding this 
effect have been proposed but an exact 
mechanism is still unknown. Local anesthesia 
prior to biopsy is a crucial part of TRUS-Bx for 
pain control. Although there is no consensus 
about anesthesia to be applied, essentially the 
pain to be felt by patient must to be reduced 
[10]. Several methods for local anesthesia 
during TRUS-Bx are available, including 
periprostatic nerve blockade, topical rectal 
administration or intraprostatic injection of 
local anesthetics [11]. In this study, we aimed 
to evaluate the effect of local anesthesia types 
on erectile function during TRUS-Bx. 
 
Methods 
Between February 2014 and February 2015, 
50 men who underwent transrectal ultrasound 
prostate biopsy (TRUS-Bx) at our institution 
were included in this prospective study. The 
institutional review board approved the 
protocol and all participants provided their 
informed consent for TRUS-Bx prior to the 
procedure. The 50 patients that were included 
in the study were randomized and divided into 
two groups according to the type of anesthesia 
used; flipping a coin was used for 
randomization. Group 1 patients (n=26) 
underwent local periprostatic anesthesia by 
injecting 6 ml of 2% lidocaine through a 18 
gauge needle in each side of the prostate gland 
guided by TRUS and whereas Group 2 
patients (n=24) were administered two 
packages of 12.5 g 2% lidocaine HCl gel 
(Cathejell) intrarectally 10 min prior to biopsy 
without any additional anesthesia. 
Indications for biopsy were elevated serum 
PSA levels (>4ng/mL) and/or suspicious 
digital rectal examination findings. Exclusion 
criteria included previous prostate biopsies, 
lidocaine allergy, hemorrhagic diathesis, 
recto-anal pathology, diabetes mellitus, 
neurologic diseases, known erectile 
dysfunction or impotence and inability to rate 
visual analog scale (VAS). Moreover, patients 
who were diagnosed with high grade prostatic 
intraepithelial neoplasia (HGPIN) and/or 
atypical small acinar proliferation (ASAP) 
and/or prostate cancer on pathologic 
evaluation of the TRUS-Bx were not included 
either. If the initial EF domain score was 
below 11 on the International Index of 
Erectile Function (IIEF), patients were 
excluded.  
All patients who had sterile urine culture 
before the procedure received an enema on the 
morning of the procedure. Oral levofloxacin 
(500 mg daily, for 5 days, started the night 
before the biopsy) was given. All procedures 
were performed by an urologist from our 
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clinic. After the patients were positioned in 
left lateral decubitus, either intrarectal 12.5 g 
2% lidocaine HCl gel (Cathejell) was applied 
digitally on the anterior anal wall and prostate 
surface or periprostatic anesthesia was 
performed with 6 ml of 2% lidocaine which 
was bilaterally injected with a 18 Gauge 
spinal needle (Chiba Biopsy Needle, Geotek, 
Turkey) into the region of the prostatic 
vascular pedicle on each side. After 
administration of the local anesthetics, the 
biopsy was performed using a 7 MHz 
transrectal probe (Siemens) to determine the 
prostatic volume and record the appearance of 
the prostate in both the transverse and 
longitudinal plane. Afterwards, 12 core 
systematic TRUS-Bx was performed via 25 
cm 18 Gauge automatic biopsy gun 
(Disposable Biopsy Device, Geotek, Turkey). 
All patients were asked to indicate the level of 
pain experienced on a visual analogue scale 
(VAS) 10 min after the TRUS biopsy. Pain 
intensity measured by VAS with 0 point/cm 
represents no pain, 10 points/cm for 
maximum intolerable pain, and is reported as 
mean and standard deviation. All 
complications such as vasovagal hypotension, 
hematuria, rectal bleeding, urethrorrhagia, 
hematospermia, lower urinary tract symptoms 
(LUTS), fever, and other possible 
complications during and after the procedure 
were recorded. Patients were invited for 
follow-up 2 months after the procedure. Data 
were obtained by four scheduled personal 
interviews and recorded in a questionnaire 
that reflected the sexual profile of patients. All 
patients had to fill in the IIEF standardized 
questionnaire and the EF domain score was 
estimated [12,13]. The first evaluation 
concerning sexual function took place 
immediately before patients were informed of 
the need for biopsy, before the actual 
procedure took place, one month after the 
biopsy, patients were evaluated again after 
pathology results were discussed, whereas the 
last evaluation took place in the second month 
after the biopsy.  
Statistical analysis 
Patient characteristics, mean VAS score and 
IIEF score were compared between the two 
groups. Group 1 patients underwent local 
periprostatic anesthesia by injecting 6 ml of 
2% lidocaine through an 18 gauge needle in 
each side of the prostate gland guided by 
TRUS and whereas Group 2 patients were 
administered two packages of 12.5 g 2% 
lidocaine HCl gel intrarectally 10 min prior to 
biopsy without any additional anesthesia. 
Mann Whitney U and Wilcoxon test were 
used for statistical analyses. A p value<0.05 
was considered statistically significant. 
Descriptive statistics were given as mean ± 
standard error. The statistical analyses were 
performed using the Statistical Package for 
the Social Sciences (SPSS.21.0) software 
program.  
 
Results 
The mean age, initial IIEF score before biopsy 
(IIEF-1), tPSA level, prostate volume and 
VAS score were 60.86± 0.95 years, 18.68, 
6.81±0.54 ng/ml, 51.10±3.82 cc and 3.5±0.26 
in all patients, respectively. The 
characteristics of the patients in group 1 and 2 
are summarized in Table 1. The difference in 
VAS scores between the groups was 
statistically significant (p<0.05). The VAS 
score in group 1 administered periprostatic 
lidocaine infiltration was lower. 
In addition, groups were evaluated in terms of 
pre-biopsy IEFF score (IIEF-1), post-biopsy 
1st month IIEF score (IIEF-2) and post-biopsy 
2nd month IIEF score (IIEF -3). The mean 
IIEF scores and statistical results are seen in 
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Table 2 and 3. In Group 1 the IIEF-1, IIEF-2, 
and IIEF-3 were different from each other 
statistically (Table 3). There was no 
statistically significant difference between 
IIEF-1 and IIEF-3 scores in group 2 (p=0,136 
z=-1,492). So it was observed that the initial 
IIEF scores were reached at the end of the 
second month in group 2 administered 12.5 g 
2% lidocaine HCl gel. 
 
Table 1. Characteristics of patients in the 
group 1 and 2. 
 
 
 
 
 
 
 
 
 
Mann Whitney U Test, P < 0.05 statistically significant.   
IIEF: International Index of Erectile Function. PSA: 
prostate-specific antigen. VAS: Visual analog scale. 
 
Table 2. Mean IIEF scores of pre-biopsy, post-
biopsy 1st and 2nd months. 
 
 
 
 
 
IIEF: International Index of Erectile Function. 
 
Table 3. Statistical results for IIEF scores.  
 
 
 
 
 
 
 
Wilcoxon Test, P < 0.05 statistically significant. IIEF: 
International Index of Erectile Function. 
Discussion 
There are several known and well-studied 
complications of prostate biopsy. These 
include hematuria and hematospermia in 20-
50% [14-16]. Patients are routinely counseled 
that hematuria and hematospermia are known 
side effects and that this has no implication on 
sexual activity. Patients are instructed that 
they may engage in sexual activity after the 
biopsy without harm to themselves or their 
partner.   
Erectile dysfunction after prostate biopsy has 
been underestimated and the exact etiology is 
unknown. Several studies have attempted to 
determine the exact incidence and etiology of 
this potential erectile dysfunction after 
prostate biopsy. In 2006, Chrisofos et al. 
directly examined the extent of ED after 
TRUS-Bx and found a non-significant 
difference regarding rates of ED at baseline 
versus 1 month and 3 months [6]. Contrary to 
this publication, later studies have found 
significant differences in the rates of ED after 
prostate biopsy [7,8,17]. 
In 2006 a small study with only 46 men did 
not show increased erectile dysfunction after 
TRUS-Bx, but the authors did claim that 
evaluating potency prior to biopsy was of 
extreme importance [6]. 
As quality of life measures have increased in 
the literature, a study in October 2010 showed 
that erectile dysfunction was more common 
early after prostate biopsy but often improved 
over time [9]. This study showed that 
periprostatic nerve block did not seem to 
change the overall effect on erections after 
biopsy. Another study showed that mean pain 
scores were lower in patients receiving 
levobupivacaine nerve block, but there was no 
change in erectile function of these patients 
[18]. 
Our study shows that a majority of men who 
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undergo prostate biopsy had a significant 
decrease in IIEF score and we found that the 
decrease in score continued until 2 months 
after the biopsy.  
There are many known and most likely still 
unknown risk factors for erectile dysfunction 
in men in the general population. We did not 
control for any of these other risk factors, 
including other medical co-morbidities such 
as coronary artery disease and diabetes 
mellitus or environmental factors such as 
smoking. We recognize the implications of 
decreased erectile function after prostate 
biopsies; therefore we are continuing to 
evaluate potential causes at our institution 
[19]. 
Although we note limitations to this study, it 
is important to recognize the many strengths 
of this study including its prospective design. 
Unlike other studies it does not have the 
potential recall biases of retrospective reviews 
of this nature. Although the IIEF-5 does not 
ask about a patient’s desire or attempt at 
erection, it is a well-known and validated 
universally accepted questionnaire to evaluate 
quality of erectile function in men. We have 
the advantage of completing this 
questionnaire pre-biopsy and at multiple time 
points post-biopsy for each patient, which 
allowed for direct comparison of each patient 
to himself as the control for changes in scores 
[19].  
TRUS-Bx is a common procedure, performed 
on an outpatient basis to diagnose prostate 
cancer. However, it has considerable impact 
on patient well-being that starts before and 
lasts for weeks after the procedure [5]. Pain 
and great discomfort are common complaints 
of patients despite the wide use of automatic 
spring-loaded biopsy guns [20]. Lately, it 
seems that an increasing number of urologists 
administer some form of anesthesia in order to 
minimize the unwanted side effects of prostate 
biopsy. One option for local anesthesia is 
periprostatic infiltration with lidocaine. 
Prostate biopsy-related pain originates from 
the autonomic fibers innervating the prostate 
that pass through the prostatic pedicle 
adjacent to the seminal vesicles. Hence, 
application of an anesthetic into this area may 
potentially reduce the resulting pain [21,22]. 
Our study supported the theory that lidocaine 
infiltration is more effective anesthesia for 
pain relief than lidocaine HCL gel only. But it 
is also not known that if type of anesthesia has 
implication on sexual activities.  
In the present study, we wished to evaluate 
whether lidocaine infiltration had any effect 
on the sexual function of patients. We 
compared a group of patients who had local 
anesthesia with periprostatic lidocaine 
infiltration to another group who were given 
12.5 g 2% lidocaine HCl gel only 
intrarectally. It is possible that erectile 
dysfunction may be caused by direct 
anatomical damage i.e. neurovascular bundle 
damage, or secondary trauma e.g. nerve 
compression due to hematoma or edema 
during infiltration with the local anesthetic 
[5]. In our study although we did not evaluate 
our patients regarding their general 
psychogenic profile, degree of anxiety, 
extroversion or introversion, it was observed 
that the initial IIEF scores were reached at the 
end of the second month in group 2 
administered 12.5g 2% lidocaine HCl gel. 
Conclusion 
Our study indicates that although local 
periprostatic anesthesia by injecting 6 ml of 
2% lidocaine provides more effective 
anesthesia for pain relief, intrarectal 12.5 g 
2% lidocaine HCl gel maintains less impact 
on erectile dysfunction for TRUS-Bx. Further 
studies are required to confirm our findings. 
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